AML’s Magnet Technology Recognized As Enabler For Cancer Treatment

Through support from the Department of Energy, the Lawrence Berkeley National Laboratory (LBNL) in collaboration with Switzerland’s Paul Scherrer Institute and leading medical company Varian Technologies are applying AML’s enabling technologies for demonstration of next generation charged particle therapy beam optics for cancer treatment such as proton and carbon therapy.

Most oncologists regard particle therapy as the preferred choice for treating tumors, it utilizes magnets for steering, focusing and correcting particle beams for delivering protons to eradicate cancerous tissue with virtually no harm to healthy tissue. However, these large, hospital size facilities are very expensive and therefore limit availability to patients’ world-wide.

One key cost driver, is the very large and heavy magnets located on the particle beam delivery “gantry” which can weigh over 600 tons. The magnets are used to bend the beam around the gantry and deliver the beam to the patient.

AML’s Double-HelixTM technologies enables magnet configurations that uniquely address such issues. For applications such as particle therapy this includes: bent (canted) and highly-pure magnetic fields; combined function fields; high ramp rates; quench free stabilized structures all protected by a comprehensive patent portfolio.

AML Enabled – Alternating-gradient canted cosine theta superconducting magnets for future compact proton gantries.